Background：Vibecotamab XmAb®14045 is a tumor-targeted antibody that contains both a CD123 binding domain and a cytotoxic T-cell binding domain CD3 in a Phase 1 clinical trial for the treatment of acute myeloid leukemia AML and other CD123-expressing hematologic malignancies. An XmAb Bispecific Fc domain serves as the scaffold for these two antigen binding domains and confers long circulating half-life, stability and ease of manufacture on vibecotamab. CD123 is highly expressed on AML cells and leukemic stem cells, and it is associated with poorer prognosis in AML patients. Engagement of CD3 by vibecotamab activates T cells for highly potent and targeted killing of CD123-expressing tumor cells.
